Literature DB >> 10414497

The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression.

F Guddo1, G Fontanini, C Reina, A M Vignola, A Angeletti, G Bonsignore.   

Abstract

Tumor progression results from complex interactions between tumor and tumor-associated host tissue. Basic fibroblast growth factor (bFGF), via activation of its receptor, FGFR-1, has been postulated to be an important inducer of host stromal response and angiogenesis. To assess the putative role of tumor-associated stromal cells and vessels in tumor progression, we studied non-small cell lung cancer (NSCLC) from 84 patients, including 51 squamous cell carcinomas and 33 nonsquamous cell carcinomas, by immunohistochemical detection. bFGF and FGFR-1 immunoreactivity was observed in tumor and in tumor-associated stromal cells and vessels. The expression of bFGF and FGFR-1 in stromal cells was higher in squamous than in non-squamous cell carcinomas (respectively, P = .007 and P = .0004). We found that bFGF and FGFR-1 expression in tumor and tumor-associated stromal cells and vessels was directly correlated with host stromal response, as assessed by intratumoral extension of stroma, but not with angiogenic response, as assessed by microvessel count. Although FGFR-1 expression of tumor cells was directly correlated with T-stage (P = .03), bFGF expressions of tumor-associated stromal cells and vessels were inversely correlated with lymph node metastasis (respectively, P = .0001 and P = .0002) and advanced pathological stage (respectively, P = .03 and P = .01). These findings suggest that bFGF might mediate host stromal response in NSCLC and that the expression of bFGF in tumor-associated stromal cells and vessels might have an inhibitory role in NSCLC progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10414497     DOI: 10.1016/s0046-8177(99)90139-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  GPC5 gene and its related pathways in lung cancer.

Authors:  Yafei Li; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

2.  FGFR1 expression and gene copy numbers in human lung cancer.

Authors:  Lukas H Kohler; Masoud Mireskandari; Thomas Knösel; Annelore Altendorf-Hofmann; Almut Kunze; Andreas Schmidt; Norbert Presselt; Yuan Chen; Iver Petersen
Journal:  Virchows Arch       Date:  2012-05-31       Impact factor: 4.064

3.  Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.

Authors:  Oddbjørn Straume; Lars Andreas Akslen
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

4.  Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.

Authors:  Cigdem Usul Afsar; Berksoy Sahin; Meral Gunaldi; Emine Kılıc Bagir; Derya Gumurdulu; Refik Burgut; Melek Erkisi; Ismail Oguz Kara; Semra Paydas; Feryal Karaca; Vehbi Ercolak
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer.

Authors:  Carmen Behrens; Heather Y Lin; J Jack Lee; Maria Gabriela Raso; Waun Ki Hong; Ignacio I Wistuba; Reuben Lotan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

6.  Platelet count: association with prognosis in lung cancer.

Authors:  Francisco Javier Gonzalez Barcala; Jose Maria Garcia Prim; Milagros Moldes Rodriguez; Julio Alvarez Fernandez; Maria Jose Rey Rey; Antonio Pose Reino; Luis Valdes Cuadrado
Journal:  Med Oncol       Date:  2009-04-21       Impact factor: 3.064

7.  The role of the tumor microenvironment in regulating angiogenesis.

Authors:  Randolph S Watnick
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

8.  Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients.

Authors:  A S Felix; R P Edwards; R A Stone; M Chivukula; A V Parwani; R Bowser; F Linkov; J L Weissfeld
Journal:  Br J Cancer       Date:  2012-05-22       Impact factor: 7.640

9.  Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro.

Authors:  M Sasaki; T Ito; M Kashima; S Fukui; N Izumiyama; A Watanabe; M Sano; Y Fujiwara; M Miura
Journal:  Mediators Inflamm       Date:  2001-10       Impact factor: 4.711

10.  ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

Authors:  S Vicent; J M López-Picazo; G Toledo; M D Lozano; W Torre; C Garcia-Corchón; C Quero; J-C Soria; S Martín-Algarra; R G Manzano; L M Montuenga
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.